Incyte's data bolster efforts to develop a new type of drug for myelofibrosis, and suggest it may be a replacement for Jakafi. Read more
Stat - Dec 07
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor program, a next-generation therapy ... Read more
Mychesco - Nov 11
WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) reported third-quarter 2025 results showing a 20% year-over-year increase in total revenue to $1.37 billion, driven by strong demand across its hematology, oncology, ... Read more
Mychesco - Nov 10
WILMINGTON, DE & CINCINNATI, OH — Incyte (NASDAQ: INCY) and Enable Injections have formed a strategic partnership to co-develop and commercialize targeted cancer therapies using Enable’s enFuse® On-Body Delivery System, ... Read more
Mychesco - Nov 09
